Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes

NCT04373967 on ClinicalTrials.gov · last registry update 2020-07-08

424 participants. Its estimated completion date, 1 December 2021, has passed with no update to the record. Primary outcome, as filed: glycated hemoglobin (HbA1c). A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: UNKNOWN
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Sponsor type: Industry
Enrollment: 424
Started: 2020-04-29
Primary completion: 2021-12-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

glycated hemoglobin (HbA1c)

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.